Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Financial Officer, Oluyemi Okupe, sold 12,313 shares of Class A Common Stock on September 17, 2026 at $28.82 per share in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2026. Following this sale, he directly held 251,804 shares and indirectly held 7,853 shares through a separate property trust.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Legal Officer, Soleil Boughton, sold 6,236 shares of Class A Common Stock on September 16, 2026 at $27.86 per share in an open market or private transaction. After this sale, the officer directly holds 304,270 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026.
Hims & Hers Health, Inc. (HIMS) reported that Chief Operating Officer Michael Chi sold Class A Common Stock in a routine insider transaction. On September 15, 2026, he sold 14,027 shares at $28.39 per share in an open market or private transaction under a Rule 10b5-1 trading plan adopted on December 1, 2025. After this sale, he continued to hold 456,660 shares of Class A Common Stock directly.
Hims & Hers Health, Inc. (HIMS) reports that its Chief Technology Officer, Mohamed Elshenawy, sold 7,954 shares of Class A Common Stock on September 15, 2026 in a sale characterized as an open market or private transaction at $28.39 per share. After this transaction, he directly holds 185,556 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025 by the reporting person.
Hims & Hers Health, Inc. (HIMS) received a Rule 144 notice from an officer, Oluyemi Okupe, covering a proposed sale of up to 12,313 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $354,860.66 and an intended sale date of September 17, 2026 on the NYSE.
The shares were acquired on August 15, 2026 via Restricted Stock Vesting from the issuer as compensation. Shares of Class A common stock outstanding were 224,935,790 as of September 17, 2026; this is a baseline figure, not the amount being sold.
Hims & Hers Health, Inc. (HIMS) is the issuer for which Soleil Boughton, identified as an officer, has filed a Rule 144 notice covering potential sales of Class A common stock through Fidelity Brokerage Services LLC. The notice lists 6,236 shares of Class A stock with an aggregate market value of $173,734.96 and notes that 224,935,790 shares of Class A were outstanding as of September 16, 2026.
The filing also describes restricted stock vesting awards of 2,775 shares on September 15, 2025 and 3,461 shares on August 15, 2026 as compensation, and reports prior sales during the past three months totaling 28,569 shares of Class A stock for aggregate proceeds of $789,773.19.
Hims & Hers Health, Inc. (HIMS) has a notice of proposed sale under Rule 144 filed for the account of officer Mohamed Elshenawy. The notice covers the potential sale of 7,954 Class A shares, arising from restricted stock vesting on August 15, 2026, held at Fidelity Brokerage Services LLC.
The filing also reports that Mohamed Elshenawy previously sold 30,040 Class A shares on June 17, 2026 for $946,260.00. Fidelity Brokerage Services LLC signed the notice as attorney-in-fact for Mohamed Elshenawy.
Hims & Hers Health, Inc. (HIMS) shareholder Michael Chi has filed a notice to sell shares under SEC Rule 144. The notice covers a proposed sale of 14,027 shares of Class A common stock through Fidelity Brokerage Services LLC, with an indicated value of $398,226.53 on the New York Stock Exchange. The shares relate to restricted stock vesting on August 15, 2026, designated as compensation. The filing also notes a prior sale of 14,027 Class A shares on June 17, 2026 for $441,850.50 within the preceding three months.
Hims & Hers Health, Inc. (HIMS) reported that Chief Legal Officer Soleil Boughton sold 3,458 shares of Class A Common Stock on September 2, 2026 at $28.33 per share in an open-market or private transaction. After this sale, Boughton directly holds 310,506 shares, and the sale was executed under a Rule 10b5-1 trading plan adopted on May 21, 2026.
Hims & Hers Health, Inc. (HIMS) is named as the issuer in a notice that Soleil Boughton, through Fidelity Brokerage Services LLC, may sell 3,458 Class A shares under Rule 144. These shares relate to restricted stock vesting on August 15, 2026. The form also lists prior sales of 25,111 Class A shares in the past three months.